RNAC
Cartesian Therapeutics, Inc. NASDAQ Listed Jun 22, 2016$8.16
Mkt Cap $239.8M
52w Low $5.60
25.7% of range
52w High $15.57
50d MA $6.88
200d MA $8.32
P/E (TTM)
-1.2x
EV/EBITDA
-0.9x
P/B
—
Debt/Equity
-0.1x
ROE
103.2%
P/FCF
-2.4x
RSI (14)
—
ATR (14)
—
Beta
0.56
50d MA
$6.88
200d MA
$8.32
Avg Volume
198.0K
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in Phase I clinical trial to enhance the treatment of methylmalonic acidemia. It is also developing biologic therapies, such as SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout; and product candidates to treat IgA-mediated diseases, including IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus, and Henoch-Schonlein purpura. In addition, the company is developing gene therapies comprising for the treatment of pompe disease, duchenne muscular dystrophy, limb-girdle muscular dystrophy, lysosomal storage disorder, and other autoimmune diseases. Further, it develops tolerogenic therapies to treat autoimmune diseases. The company has license and collaboration agreements with Ginkgo Bioworks Holdings, Inc.; Genovis AB (publ.); Cyrus Biotechnology, Inc.; IGAN Biosciences, Inc.; Astellas Therapeutics, Inc.; Takeda Pharmaceuticals USA, Inc.; Swedish Orphan Biovitrum AB (publ.); Sarepta Therapeutics, Inc.; Asklepios Biopharmaceutical, Inc.; Massachusetts Institute of Technology; and Shenyang Sunshine Pharmaceutical Co., Ltd. Selecta Biosciences, Inc. was incorporated in 2007 and is headquartered in Watertown, Massachusetts.
65 Grove Street · Watertown, MA 02472 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 30, 2026 | AMC | -0.84 | -1.46 | -73.8% | 6.22 | -0.3% | +0.0% | +11.4% | +6.6% | +12.9% | -2.2% | — |
| Mar 9, 2026 | AMC | -0.82 | -1.38 | -68.3% | 9.02 | +0.9% | -5.2% | -3.4% | -1.7% | -9.0% | -0.8% | — |
| Nov 6, 2025 | AMC | -0.81 | -1.38 | -70.4% | 7.55 | -0.9% | +4.2% | -8.0% | +0.8% | +3.8% | -4.6% | — |
| Aug 7, 2025 | AMC | -0.76 | 0.50 | +165.8% | 10.54 | -0.3% | -0.1% | +5.4% | +2.1% | +3.4% | -2.4% | — |
| May 8, 2025 | AMC | -0.61 | -0.68 | -11.5% | 10.42 | -0.4% | -5.0% | +5.5% | -2.3% | -2.2% | +4.5% | — |
| Mar 20, 2025 | AMC | -0.78 | -0.59 | +24.4% | 15.93 | +2.8% | +0.8% | -0.7% | -0.1% | -6.5% | -3.5% | — |
| Nov 7, 2024 | AMC | -0.78 | -0.69 | +11.5% | 20.78 | +1.6% | -0.1% | -4.7% | -14.4% | +1.1% | -0.6% | — |
| Aug 8, 2024 | AMC | -1.07 | 0.54 | +150.5% | 12.87 | +0.3% | +3.9% | -5.0% | +7.6% | -4.3% | +10.5% | — |
| May 8, 2024 | AMC | -0.81 | -1.97 | -143.2% | 23.25 | -2.2% | -6.0% | -3.2% | +1.3% | +15.4% | +7.7% | — |
| Mar 7, 2024 | AMC | -0.30 | -2.40 | -700.0% | 19.31 | +2.0% | -0.6% | -0.2% | -8.0% | -6.5% | -2.7% | — |
| Nov 13, 2023 | AMC | -2.10 | -2.40 | -14.3% | 26.44 | -8.5% | +21.4% | -9.4% | +8.3% | +1.9% | +4.7% | — |
| Aug 17, 2023 | AMC | -0.09 | -0.07 | +22.2% | 33.60 | -4.5% | +0.9% | +1.8% | +1.7% | -0.9% | -3.4% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 1 | Wedbush | Maintains | Outperform → Outperform | — | $6.22 | $6.20 | -0.3% | +0.0% | +11.4% | +6.6% | +12.9% | -2.2% |
| Mar 10 | Wedbush | Maintains | Outperform → Outperform | — | $9.02 | $9.10 | +0.9% | -5.2% | -3.4% | -1.7% | -9.0% | -0.8% |
| Mar 9 | Needham | Maintains | Buy → Buy | — | $6.85 | $6.55 | -4.4% | +31.7% | -5.2% | -3.4% | -1.7% | -9.0% |
| Mar 9 | Cantor Fitzgerald | Upgrade | Neutral → Overweight | — | $6.85 | $6.55 | -4.4% | +31.7% | -5.2% | -3.4% | -1.7% | -9.0% |
| Jan 9 | Needham | Maintains | Buy → Buy | — | $8.12 | $8.07 | -0.6% | +1.0% | -11.3% | +5.4% | -0.3% | -3.7% |
| Nov 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.62 | $7.55 | -0.9% | -6.2% | +0.0% | +1.3% | +2.6% | -1.5% |
| Nov 14 | BTIG | Maintains | Buy → Buy | — | $7.23 | $7.50 | +3.7% | +3.2% | -1.1% | +3.3% | -6.2% | +0.0% |
| May 8 | Needham | Maintains | Buy → Buy | — | $10.15 | $10.26 | +1.1% | +2.7% | -5.0% | +5.5% | -2.3% | -2.2% |
| Apr 9 | Needham | Maintains | Buy → Buy | — | $9.52 | $9.34 | -1.9% | +19.3% | -8.8% | +3.0% | +21.8% | -7.9% |
| Apr 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.52 | $9.34 | -1.9% | +19.3% | -8.8% | +3.0% | +21.8% | -7.9% |
| Mar 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $16.61 | $16.58 | -0.2% | -4.9% | -8.6% | +1.1% | +5.9% | +3.0% |
| Mar 13 | Needham | Maintains | Buy → Buy | — | $17.48 | $17.13 | -2.0% | -5.0% | -4.9% | -8.6% | +1.1% | +5.9% |
| Jan 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $19.42 | $19.32 | -0.5% | +2.9% | -3.8% | +0.8% | -0.4% | +3.0% |
| Jan 27 | Needham | Maintains | Buy → Buy | — | $19.20 | $19.10 | -0.5% | +1.1% | +2.9% | -3.8% | +0.8% | -0.4% |
| Jan 13 | Needham | Maintains | Buy → Buy | — | $16.84 | $16.56 | -1.7% | +8.8% | -1.7% | +5.2% | -0.1% | +1.9% |
| Dec 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $20.08 | $20.68 | +3.0% | +9.6% | +4.6% | +9.3% | -2.8% | -6.6% |
| Dec 3 | Needham | Maintains | Buy → Buy | — | $19.57 | $19.80 | +1.2% | +2.6% | +9.6% | +4.6% | +9.3% | -2.8% |
| Nov 25 | Needham | Maintains | Buy → Buy | — | $18.87 | $19.42 | +2.9% | -5.1% | +4.1% | -4.0% | +5.1% | +3.9% |
| Nov 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $20.78 | $21.11 | +1.6% | -0.1% | -4.7% | -14.4% | +1.1% | -0.6% |
| Nov 8 | Needham | Maintains | Buy → Buy | — | $20.78 | $21.11 | +1.6% | -0.1% | -4.7% | -14.4% | +1.1% | -0.6% |
| Oct 16 | Needham | Maintains | Buy → Buy | — | $20.63 | $20.78 | +0.7% | +6.1% | -0.8% | +5.4% | -1.4% | -1.7% |
| Sep 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $16.07 | $16.00 | -0.4% | +4.2% | -4.4% | +3.9% | -6.0% | +5.8% |
| Sep 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.12 | $13.05 | -0.5% | +2.6% | +4.3% | -7.5% | +1.1% | +13.3% |
| Aug 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.37 | $13.33 | -0.3% | -5.0% | +7.6% | -4.3% | +10.5% | -1.6% |
| Aug 9 | Needham | Maintains | Buy → Buy | — | $12.87 | $12.91 | +0.3% | +3.9% | -5.0% | +7.6% | -4.3% | +10.5% |
| Jul 8 | Needham | Maintains | Buy → Buy | — | $16.97 | $16.87 | -0.6% | -0.9% | -0.2% | +0.8% | +5.0% | -0.1% |
| Jul 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $15.77 | $16.16 | +2.5% | +11.7% | -3.7% | -0.9% | -0.2% | +0.8% |
| Jul 3 | Canaccord Genuity | Maintains | Buy → Buy | — | $15.77 | $16.16 | +2.5% | +11.7% | -3.7% | -0.9% | -0.2% | +0.8% |
| Jul 2 | Oppenheimer | Downgrade | Outperform → Peer Perform | — | $24.27 | $17.97 | -26.0% | -35.0% | +11.7% | -3.7% | -0.9% | -0.2% |
| Jul 1 | Needham | Maintains | Buy → Buy | — | $27.01 | $26.51 | -1.9% | -10.1% | -35.0% | +11.7% | -3.7% | -0.9% |
| Jun 24 | Oppenheimer | Maintains | Outperform → Outperform | — | $22.80 | $22.36 | -1.9% | +1.1% | +4.4% | +2.9% | +15.2% | -5.3% |
| Jun 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $27.29 | $26.82 | -1.7% | -14.5% | -6.7% | +5.2% | -0.4% | +1.1% |
| Jun 14 | Oppenheimer | Maintains | Outperform → Outperform | — | $29.29 | $28.77 | -1.8% | -6.8% | -14.5% | -6.7% | +5.2% | -0.4% |
| May 23 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $25.46 | $25.84 | +1.5% | +0.0% | -3.5% | +15.0% | +2.6% | +8.4% |
| May 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $23.25 | $22.73 | -2.2% | -6.0% | -3.2% | +1.3% | +15.4% | +7.7% |
| May 8 | Needham | Maintains | Buy → Buy | — | $23.21 | $23.00 | -0.9% | +0.2% | -6.0% | -3.2% | +1.3% | +15.4% |
| Apr 23 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $18.26 | $20.26 | +11.0% | +12.8% | +0.6% | +0.9% | +0.6% | +4.6% |
| Apr 10 | Needham | Maintains | Buy → Buy | — | $13.99 | $13.44 | -3.9% | +16.7% | +10.5% | +7.5% | -2.1% | -1.2% |
| Mar 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $17.41 | $16.80 | -3.5% | +8.9% | +13.8% | +7.0% | -8.5% | +1.5% |
| Mar 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $19.20 | $19.05 | -0.8% | -0.2% | -8.0% | -6.5% | -2.7% | +8.4% |
| Mar 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $20.17 | $21.23 | +5.3% | +4.1% | -8.0% | -0.6% | -0.2% | -8.0% |
| Aug 18 | SVB Leerink | Downgrade | Outperform → Market Perform | — | $33.60 | $32.10 | -4.5% | +0.9% | +1.8% | +1.7% | -0.9% | -3.4% |
| Aug 18 | Needham | Maintains | Buy → Buy | — | $33.60 | $32.10 | -4.5% | +0.9% | +1.8% | +1.7% | -0.9% | -3.4% |
| Aug 18 | Mizuho | Maintains | Buy → Buy | — | $33.60 | $32.10 | -4.5% | +0.9% | +1.8% | +1.7% | -0.9% | -3.4% |
| Aug 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $33.60 | $32.10 | -4.5% | +0.9% | +1.8% | +1.7% | -0.9% | -3.4% |
| Mar 22 | Mizuho | Maintains | Buy → Buy | — | $37.80 | $37.80 | +0.0% | +11.9% | +2.8% | -2.8% | -5.7% | -3.8% |
| Mar 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $37.80 | $37.80 | +0.0% | +11.9% | +2.8% | -2.8% | -5.7% | -3.8% |
| Jan 31 | Canaccord Genuity | Maintains | Buy → Buy | — | $52.80 | $53.85 | +2.0% | +0.6% | +3.4% | +1.6% | -1.1% | -0.5% |
| Jun 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $37.20 | $39.30 | +5.6% | +1.6% | +0.0% | +11.1% | -5.0% | +0.8% |
| Jun 14 | Needham | Maintains | Buy → Buy | — | $33.60 | $33.00 | -1.8% | -6.2% | +9.5% | +16.5% | -7.5% | +1.6% |
No insider trades available.
8-K
Cartesian Therapeutics, Inc. -- 8-K Filing
Cartesian Therapeutics reported Q1 2026 results and highlighted Descartes-08 as a promising late-stage cell therapy candidate with potential to address unmet autoimmune disease treatment needs through durable response.
Apr 30
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
RNAC's executive change signals potential strategic shifts and management uncertainty that could impact operational direction and investor confidence in near-term performance.
Mar 30
8-K
Cartesian Therapeutics, Inc. -- 8-K Filing
Cartesian Therapeutics (RNAC) expects 2026 to be transformative as it advances its Descartes-08 cell therapy candidate across multiple autoimmune disease indications in late-stage clinical development.
Mar 9
Data updated apr 26, 2026 11:12pm
· Source: massive.com